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Abstract
Purpose To assess the accuracy of [68Ga]-PSMA-11 PET/CT or [68Ga]-PSMA-11 PET/MRI (PSMA-11 PET/CT(MRI)) for
lymph node (LN) staging using salvage LN dissection (SLND) in patients with biochemical recurrence (BCR) after radical
prostatectomy (RP).
Patients and methods In a prospective study, 65 consecutive patients who developed BCR after RP underwent SLND after
PSMA-11 PET/CT(MRI) between 2014 and 2018. Extended SLND up to the inferior mesenteric artery was performed in all
patients. Regional and template-based correlations between the presence of LN metastases on histopathology and whole-body
PSMA-11 PET/CT(MRI) results were evaluated. The diagnostic accuracy of PSMA-11 PET/CT(MRI) was also evaluated in
relation to PSA level at the time of SLND.
Results The median age of the patients at the time of SLND was 65 years (IQR 63–69 years) and the median PSA level was
1.4 ng/ml (IQR 0.8–2.9 ng/ml). Before SLND, 50 patients (77%) had additional therapy after RP (26.2% androgen-deprivation
therapy and 50.8% radiotherapy). The median number of LNs removed on SLNDwas 40 (IQR 33–48) and the median number of
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positive nodes was 4 (IQR 2–6). LN metastases were seen in 13.8% of resected LNs (317 of 2,292). LNs positive on PSMA-11
PET/CT(MRI) had a median diameter of 7.2 mm (IQR 5.3–9 mm). Metastatic LNs in regions negative on PSMA-11 PET had a
median diameter of 3.4 mm (IQR 2.1–5.4 mm). In a regional analysis, the sensitivity of PSMA-11 PET/CT(MRI) ranged from
72% to 100%, and the specificity from 96% to 100%. Region-specific positive and negative predictive values ranged from 95%
to 100% and 93% to 100%, respectively.
Conclusion PSMA-11 PET/CT(MRI) has a very good performance for the identification of LN metastases in patients with BCR
after RP. The high diagnostic accuracy in the regional and subregional analyses demonstrates the potential of this approach to
enable a region-directed instead of a complete bilateral therapeutic intervention. The performance of PSMA-11 PET/CT(MRI) is
dependent on the PSA level and the size of the metastatic deposit.
Keywords Biochemical recurrence . Hybrid imaging . PET/CT . PET/MRI . PSMA ligand . Salvage lymph node dissection
Introduction
Despite effective local therapy with curative intent, about one-
third of patients with localized prostate cancer (PC) experi-
ence biochemical recurrence (BCR) [1–3]. Rising prostate-
specific antigen (PSA) in these patients may be due to
locoregional recurrence, distant metastases, or both [2, 4, 5].
While patients with distant metastases often require systemic
therapy, those with locoregional failure are candidates for
targeted locoregional salvage therapies with or without a lim-
ited course of androgen-deprivation therapy (ADT) [2, 6].
Indeed, locoregional therapy such as salvage radiotherapy or
lymphadenectomy has been shown to result in potentially du-
rable local and distant cancer control [7]. Contemporary re-
ports indicate that approximately one-third of patients treated
with radical prostatectomy (RP) do not receive a pelvic lymph
node dissection (PLND) [8]. The rate and extent of PLND as
well as the number of lymph nodes (LNs) removed have con-
tinuously decreased over the last three decades. Consequently,
the frequency of “limited” pelvic LN metastases as a cause of
BCR is expected to increase [8].
Novel imaging techniques such as positron emission to-
mography (PET) with specific radiopharmaceuticals targeting
prostate-specific membrane antigen (PSMA), that avidly ac-
cumulates in PC foci, have improved tumour staging [9] and
have led to earlier detection and localization of specific me-
tastases at the time of BCR [2, 10–12].While choline PET has
shown promising early results, the rates of false-positive and
false-negative results limit its widespread use, especially in
low-volume disease such relapse in single LNs [13].
Furthermore, the performance of choline PET/CT is lower in
patients with low PSA levels, limiting its value for guiding
“lesion-targeted” salvage lymph node dissection (SLND) [1,
14, 15]. In contrast, [68Ga]-PSMA-11 ([68Ga]Ga-PSMAHBED-
CC; PSMA-11) has shown very promising diagnostic perfor-
mance in patients with rising but still low PSA levels after
primary local therapy with curative intent such as RP [12,
16, 17]. Indeed, PSMA-11 PET imaging has shown very good
results in patients with LN metastasis [17].
We therefore hypothesized that PSMA-11 PET imaging
could help reliably identify patients who harbour LN-only
metastases after RP and help localize them with sufficient
accuracy to allow local therapy. Given the currently unmet
need to accurately identify isolated LN metastases in patients
with BCR after RP, we performed a prospective study to as-
sess the performance of PSMA-11 PET/CTor PSMA-11 PET/
MRI (PSMA-11 PET/CT(MRI)) prior to SLND. Our primary
endpoint was to assess the concordance between PSMA-
positive LNs and histopathology as the confirmatory test.
Our second aim was to determine the size of LN metastasis
needed to obtain a reliably positive PSMA-11 PET signal.
Materials and methods
Patients
We performed a prospective analysis in the scope of an ongo-
ing clinical trial (ClinicalTrials.gov NCT02974075,
clinicaltrials.gov) in patients with BCR following RP from
May 2014 to February 2018. A total of 65 consecutive
patients had LN-only metastasis on PSMA-11 PET/
CT(MRI) and agreed to undergo an open SLND. BCR was
defined as two consecutive increases in PSA level above 0.
2 ng/ml. None of the patients had evidence of local recurrence,
or visceral or bone metastasis at the time of SLND. All
resected LNs were formalin-fixed, paraffin-embedded and
processed according to the American Joint Committee on
Cancer TNM staging system and WHO/ISUP 2005 system
by a dedicated urohistopathologist who was blinded to the
imaging results [18]. PSMA-11 PET/CT(MRI) without addi-
tional imaging was performed to assess the site of BCR after
SLND. Follow-up schedules included physical examination
and PSA measurement every 3 months for the first 2 years
and then semiannually. In patients with an increase in PSA
level above the nadir, novel imaging consisting of PSMA-11
PET and/or CT and bone scan was performed. The ethics
committee of the Medical University of Vienna approved the
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study (permit 1460). All patients provided written informed
consent prior to SLND. The data are presented according to
the STARD criteria [19].
Imaging protocol
PET/CT and PET/MRI were performed as previously de-
scribed [12]. Briefly, [68Ga]-PSMA-11 at 2 MBq per kg
body weight was injected intravenously 60 min before the
PET/MRI(CT) acquisition was started. PET/MRI was per-
formed on a Biograph mMR (Siemens, Germany),
consisting of an MRI-compatible PET detector integrated
with a 3.0-T whole-body MRI scanner. The PET compo-
nent used a three-dimensional acquisition technique and
offered an axial field of view (FOV) of approximately
23 cm and a transverse FOV of 45 cm with a sensitivity
of 13.2 cps/kBq. For improved image quality, forced di-
uresis was induced with 20 mg of furosemide adminis-
tered intravenously before PSMA, and all patients under-
going PET/MRI received a bladder catheter.
Local PET of the pelvis included a 10-min list-mode
acquisition starting 60 min after injection. Partial body
PET (skull base to thighs) was performed with four bed
pos i t ions , each wi th a 4 -min s inogram mode .
Reconstruction parameters for PET were: three iterations
per 21 subsets, and summation of the 10-min pelvic ac-
quisition for visual and semiquantitative analysis. MRI-
based attenuation correction was applied using DIXON
VIBE sequences comprising in-phase and opposed-phase,
and fat-saturated and water-saturated images.
PET/CTwas performed from the vertex to the upper thighs
using a 64-row multidetector hybrid system (Biograph
TruePoint 64; Siemens, Erlangen, Germany), with an axial
FOV of 216 mm, a PET sensitivity of 7.6 cps/kBq and a
transaxial PET resolution of 4–5 mm (full-width at half-max-
imum). PET acquisition parameters were 4 min per bed posi-
tion, four iterations per 21 subsets, 5-mm slice thickness, and
168 × 168 matrix, using the point-spread-function-based re-
construction algorithm TrueX. CT maps were used for PET
attenuation correction.
The MRI protocol included native axial T2w turbo spin
echo, coronal T1w spin echo and axial diffusion-weighted
imaging sequences of the pelvis, and T2w HASTE and
DIXON VIBE partial body imaging. The MRI parameters
have been described in detail previously [12]. PET/MRI was
performed in 42 patients.
Venous-phase contrast-enhanced CT was performed after
intravenous injection of 100 ml of a tri-iodinated, non-ionic
contrast medium at a rate of 2 ml/s with tube voltage 120 mA,
tube current 230 kV, collimation 64 × 0.6 mm, 3-mm slice
thickness at a 2-mm increment, and 512 × 512 matrix. PET/
CTwas performed in 23 patients.
Image analysis
PET/MRI and PET/CT images were reviewed separately
by two experienced certified nuclear medicine physicians
using a Hermes Hybrid 3D workstation (Hermes Medical
Solutions, Stockholm) for PET/MRI and PET/CT. MR/CT
images were assessed according to section 3 of RECIST
1.1 (Measurability of Tumors at Baseline) using AGFA
IMPAXX EE software for MRI and CT [20]. Every focus
showing differentially increased uptake compared to the
surrounding background uptake in a visible morphologi-
cal structure (e.g. LN) was considered a positive finding.
Foci showing slight increases in uptake of 68Ga-PSMA in
the area of the paravertebral sympathetic ganglia were
ignored, as they are known to be false-positive [21].
Documentation was carried out concerning LNs according
to the scheme shown in Fig. 1.
Salvage lymph node dissection
All patients underwent full bilateral superextended pelvic
LN dissection up to the level of the inferior mesenteric
artery. The SLND templates included all the LNs from the
following major regions: right and left pelvis, and
presacral and retroperitoneal regions. For the subregional
analysis, the pelvic templates included nine subregions:
bilateral common iliac, external iliac, obturator and inter-
nal iliac regions and the presacral region. The retroperito-
neal templates comprised three subregions: periaortic,
interaortocaval and precaval LNs between the aortic bifur-
cation and the inferior mesenteric artery. The external,
internal and obturator subregions were evaluated as a
group to minimize localization/attribution errors. All
SLND were performed by the same surgeon (S.F.S.) ac-
cording to a standard prespecified surgical protocol, and
the LNs were sent separately to histopathology according
to the prespecified templates.
Histopathological methods and analysis
Formalin-fixed LN specimens were completely embedded
in paraffin and processed according to the protocol de-
scribed by Rais-Bahrami et al. [22]. Paraffin-embedded
sections of thickness 2 µm were routinely stained with
haematoxylin and eosin, and where required immunohisto-
chemical staining with a pancytokeratin antibody (AE1/3,
dilution 1:100) was performed to exclude micrometastases.
Statistical analysis
This was a prospective study designed to test the perfor-
mance of SLND in patients with pelvic-only LN metasta-
ses on PSMA-11 PET after RP. We report the data of the
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first 65 patients who met our predefined inclusion criteria.
A descriptive analysis of the whole cohort was performed.
Diagnostic performance from the regional and subregional
analyses was compared with histopathology after SLND as
the confirmatory test. A confirmed LN metastasis in a re-
gion or subregion was considered positive for the template
analysis. The sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) with cor-
responding confidence intervals (CI) of PSMA-11 PET/
CT(MRI) were estimated for the assessment of LN metas-
tasis per region and subregion using contingency tables.
Statistical associations were tested using the chi-squared
test or Fisher’s exact test as appropriate. Statistical analy-
ses were performed using STATA 13 (Stata Corp., College
Station, TX, USA) with an alpha level of 0.05 indicating
statistical significance. Accuracy was calculated using
MedCalc Software (Ostend, Belgium) according to the fol-
lowing formula: ¼ TPþTNTPþTNþFPþFN, where TP is true posi-
tive, TN is true negative, FP is false positive and FN is
false negative. The images were reviewed prior to SLND.
The pathology and PSMA-11 PET/CT(MRI) were each
interpreted blinded to the result of the other.
Results
Baseline characteristics of patients
Overall, 65 consecutive patients meeting the inclusion
criteria were included in the study. Table 1 summarizes
patient and tumour characteristics at the time of RP and
SLND. About three-quarters of patients showed
extraprostatic extension on their RP specimens and one-
fifth initially harboured LN metastases at the time of RP.
Before SLND, 50 patients (76.9%) had additional therapy
after RP with 17 (26.2%) receiving ADT and 33 (50.8%)
radiotherapy. Intraoperative and postoperative complica-
tions were reported in 7 patients (10.8%) and 21 patients
(32.3%), respectively. The detailed oncological and peri-
operative and postoperative outcomes, including compli-
cations of SLND and postoperative complications, will be
reported separately as a part of an ongoing clinical trial.
Findings of PSMA-11 PET/CT(MRI) and SLND
On PSMA-11 PET/CT(MRI), all but two patients (97%)
had positive LNs in the pelvic region only. Two patients
had retroperitoneal LN involvement in addition to pelvic
LNs. Figure 2 shows the numbers of harvested LN in each
region and subregion, the corresponding numbers of pos-
itive LN, and the rates of positivity. Metastases were de-
tected in 13.8% of LNs resected on SLND (317 of 2,292).
The largest number of resected LNs was from the right
common iliac subregion (329) followed by the retroperi-
toneal region (312). The rate of positive LNs across all
subregions ranged from 8% to 16.9%. The largest percent-
age of positive LNs was in the right internal iliac subre-
gion (16.9%) followed by the left internal iliac region
(16.8%). The median diameter of LNs positive on
PSMA-11 PET/CT(MRI) was 7.2 mm (IQR 5.3–9 mm),
whereas the median diameter of false-negative LNs was
3.4 mm (IQR 2.1–5.4 mm; p = 0.01).
Fig. 1 Schematic tomographic
image of the templates for
patients undergoing complete
bilateral extended salvage lymph
node dissection
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Regional and subregional analyses
with corresponding histopathology after SLND
The sensitivity, specificity, PPV, NPVand diagnostic accuracy
in the regional and subregional analyses are presented in
Table 2. Overall, the diagnostic accuracy for all the subregions
ranged from 88% to 99%. The accuracies in detecting LN
metastases in the right and left pelvic regions were 95%
(95% CI 87.1–99%) and 99% (95% CI 91.7–100%), respec-
tively, and in the presacral region and retroperitoneal regions
Table 1 Baseline characteristics
of 65 patients with prostate cancer
who underwent salvage lymph
node dissection for biochemical
recurrence after radical
prostatectomy
Characteristic Value
Age at RP (years), median (IQR) 61 (59–66)
PSA level prior to RP (ng/ml), median (IQR) 9 (7–12)
Pathological stage at RP, n (%)
pT2 12 (18.5)
pT3a 30 (46.6)
pT3b 20 (30.8)
pT4 3 (4.6)
Lymph node stage at RP, n (%)
pN0 57 (87.7)
pN1 8 (12.3)
Number of lymph nodes removed at RP, median (IQR) 8 (5–12)
Positive surgical margin, n (%) 23 (35.4)
Time to BCR (months), median (IQR) 12 (2–23)
Therapy after RP, n (%)
Hormonal 17 (26.2)
Radiation 33 (50.8)
Pathological Gleason score, n (%)
<7 1 (1.5)
7 (3 + 4) 14 (21.5)
7 (4 + 3) 20 (30.8)
>7 30 (46.2)
Age at SLND (years), median (IQR) 65 (63–69)
PSA level at SLND (ng/ml), median (IQR) 1.4 (0.8–2.9)
Number of lymph nodes removed, median (IQR) 40 (33–48)
Number of positive lymph nodes removed, median (IQR) 4 (2–5)
Time from SLND to last follow-up (months), median (IQR) 13 (7–22)
BCR after SLND, n (%) 35 (61.4)
Operative time (minutes), median (IQR) 210 (180–230)
Length of hospital stay (days), median (IQR) 6 (6–8)
RP radical prostatectomy, SLND salvage lymph node dissection, IQR interquartile range, BCR biochemical
recurrence, PSA prostate-specific antigen
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Eur J Nucl Med Mol Imaging (2019) 46:2169–2177 2173
were both 95% (95% CI 87.1–99%). The accuracy in detect-
ing LN metastases in the common and external iliac LNs
ranged from 88% to 97%, and the accuracy in the internal iliac
and obturator regions was >95%. As a test for predicting the
probability of the presence of LN metastasis, the PPVs were
higher than 92% and reached 100%. The NPVs ranged from
86% to 98%. Grouping external, internal and obturator LNs
together, both the PPV and NPV in detecting LN metastases
ranged from 97% to 100% in all regions (the grouping was
done to account for possible attribution bias in location assign-
ment on imaging versus surgery).
Subgroup analysis
The performance of PSMA-11 PET/CT(MRI) was evaluated in
relation to PSA level at the time of SLND (Table 3). The PPV in
patients with a PSA level ≥1.4 ng/ml (the median PSA level in
our cohort) was almost always 100% in all regions and subre-
gions except the presacral region, where it was 93% (95% CI
67.5–99). In patients with a PSA level <1.4 ng/ml, the PPVin the
regional analysis ranged from 94% to 100%, and in the subre-
gional analysis, ranged from 50% in the right common iliac LNs
to 100% in the external and internal iliac and obturator LNs. No
statistically significant differences in PSMA-11 PET
performance in relation to primary Gleason score and time to
BCR were found. Furthermore, no differences in imaging per-
formance were found between PSMA-11 PET/CT (in 23 pa-
tients) and PSMA-11 PET/MRI (in 42 patients).
Discussion
In this prospective study, PSMA-11 PET/CT(MRI) showed a
high diagnostic accuracy for nodal relapse after RP according
to topographical location using histopathological results as the
confirmatory test. All men were included in a consecutive
manner without any obvious selection bias. All underwent a
complete bilateral template-based SLND for assumed LN-
only relapse based on PSMA-11 PET imaging. The high per-
formance, as illustrated by the high PPV, of PSMA-11 PET/
CT(MRI) was confirmed by regional and subregional analy-
ses. The diagnostic accuracy of PSMA-11 PET/CT(MRI) in-
creased with the size of LN metastatic deposits and PSA
levels. Nevertheless, its performance was still good in patients
with small metastatic deposits and in those with low PSA
levels. The data show that PSMA-11 PET/CT(MRI) detects
LN metastases with high PPVand NPV. This suggests a pos-
sible role of site-directed surgical intervention in patients with
Table 2 Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of PSMA-11 PET/CT(MRI) in 65 patients from the
regional and subregional analyses
Sensitivity
(95% CI), %
Specificity
(95% CI), %
Positive predictive value
(95% CI), %
Negative predictive value
(95% CI), %
Diagnostic accuracy
(95% CI), %
Regional analysis
Pelvic (right) 94.6 (81.8–99.3) 96.4 (81.7–9.9) 97.2 (83.6–99.6) 93.1 (77.8–98.1) 95.4 (87.1–99)
Pelvic (left) 100 (90.5–100) 96.4 (81.7–99.9) 97.4 (84.4–99.6) 100 98.5 (91.7–100)
Presacral 90.9 (70.8–98.9) 97.7 (87.7–99.9) 95.2 (74.2–99.3) 95.5 (84.8–98.8) 95.4 (87.1–99)
Retroperitoneal 72.7 (39–939) 100 (93.4–100) 100 94.7 (87.3–97.9) 95.4 (87.1–99)
Subregional analysis
Common iliac
Right 65 (40.8–84.6) 97.8 (88.2–99.9) 92.9 (64.6–98.9) 86.3 (77.6–92) 87.7 (77.2–94.5)
Left 78.6 (49.2–95.3) 98 (89.6–100) 91.7 (60.8–98.7) 94.3 (85.9–97.9) 93.9 (85–98.3)
External iliac
Right 80 (51.9–95.7) 100 (92.3–100) 100 94.3 (85.8–97.9) 95.4 (87.1–99)
Left 92.9 (66.1–99.8) 98 (89.6–100) 92.9 (65–98.9) 98 (88.3–99.7) 96.9 (89.3–99.6)
Internal iliac
Right 95 (75.1–99.9) 100 (92–100) 100 97.8 (86.7–99.7) 98.4 (91.6–100)
Left 87 (66.4–97.2) 100 (91.6–100) 100 93.3 (83–97.6) 95.4 (87.1–99)
Obturator
Right 89.5 (66.9–98.7) 100 (92.3–100) 100 95.8 (86.1–98.8) 96.9 (89.3–99.6)
Left 84.2 (60.4–96.6) 100 (92.3–100) 100 93.9 (84.4–97.7) 95.4 (87.1–99)
External, internal and obturator combined
Right 97.1 (84.7–99.9) 100 (88.8–100) 100 96.9 (81.8–99.5) 98.5 (91.7–100)
Left 100 (90.3–100) 96.6 (82.2–99.9) 97.3 (84–99.6) 100 98.5 (91.7–100)
p < 0.001, Fisher’s exact test among all regions and subregions
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LN-only metastasis after RP, reinforcing the promise of per-
sonalized medicine in PC.
Conventional morphological imaging techniques such as CT
and MRI have suboptimal diagnostic performance in detecting
LNmetastases with sensitivities ranging from 13% to 40% [23].
Despite the ability of PET/CT with choline analogues to detect
LNs missed by conventional cross-sectional imaging, its perfor-
mance in identifying single LNmetastases or the extent of nodal
relapse is poor. This is mainly due to the limited spatial resolu-
tion of most PETscanners (5 mm) and the different biochemical
mechanism (choline as a metabolic marker rather than PSMA-
11 as a receptor-binding ligand) [14]. In agreement with our
data, the detection of recurrence and its location has been found
to depend largely on LN size and PSA level [14]. In contrast to
the findings of previous studies, the primary Gleason score and
the time to BCR were not associated with PSMA-11 PET per-
formance in this study. This might be explained by our highly
selected cohort of patients with BCR, who were included in the
study and underwent SLND only if LN-only recurrence was
considered to be present with no evidence of further distant
PSMA-avid lesions. Furthermore, almost 80% of the patients
in our cohort had high-risk or unfavourable intermediate-risk
disease based on the histopathological specimen from RP, and
only a few patients had low-risk disease (1 patient) and
favourable intermediate-risk disease (14 patients). This might
also have limited the difference in PSMA-11 PET performance
in relation toGleason score.Moreover, the reported lesion-based
pooled sensitivity was limited [24]. Current literature indicates
that the performance of PSMA PET is higher in patients with
higher PSA levels [11]. In line with this finding, PSMA PET
showed higher diagnostic performance in the group of patients
with PSA levels higher than the median (1.4 ng/ml).
Nevertheless, the accuracy of PSMA PET was still high in pa-
tients with PSA levels <1.4 ng/ml.
PSMA-11 PET showed promising potential in identifying
the sites of BCR because of the high-affinity binding of
PSMA to folate hydrolase of PC cells [25], and is gaining
worldwide popularity as a clinically relevant staging tool,
even in men with low PSA levels (i.e. <1 ng/ml) at recurrence
[26]. Indeed, positive PSMA-11 PET/CT scans have been
reported in 44% and 79% of patients with PSA levels ≤1
and 1–2 ng/ml, respectively [27].
Table 3 Positive and negative predictive values for PSMA-11 PET/CT(MRI) in 65 patients in relation to PSA level at the time of imaging
PSA level at the time of SLND (ng/ml)a
<1.4 ≥1.4
Positive predictive value
(95% CI), %
Negative predictive value
(95% CI), %
Positive predictive value
(95% CI), %
Negative predictive value
(95% CI), %
Regional analysis
Pelvic (right) 95 (74.2–99.2) 100 100 85.7 (61.7–95.7)
Pelvic (left) 94.4 (71.8–99.1) 100 100 100
Presacral 100 97 (84.2–99.9) 93.3 (67.5–99) 94.1 (70.6–99)
Retroperitoneal 100 96.7 (84.2–99.4) 100 92.6 (79.5–97.6)
Subregional analysis
Common iliac
Right 50 (7.1–92.9) 90.3 (84.1–94.3) 100 80 (63.1–90.3)
Left 80 (34.5–96.8) 89.3 (77.9–95.2) 100 100
External iliac
Right 100 96.2 (80–99.4) 100 92.6 (79.5–97.6)
Left 85.7 (46.7–97.6) 100 100 96 (79.3–99.3)
Internal iliac
Right 100 96.3 (80.9–99.4) 100 100
Left 100 90.9 (73.7–97.3) 100 95.7 (77.4–99.3)
Obturator
Right 100 96.2 (80–99.4) 100 95.5 (76.4–99.3)
Left 100 96.3 (80.9–99.4) 100 90.9 (73.8–97.3)
External, internal and obturator combined
Right 100 100 100 93.3 (67.6–99)
Left 95 (74.2–9.2) 100 100 100
a 33 patients with a PSA level <1.4 ng/ml, median 0.8 ng/ml (IQR 0.6–1 ng/ml); 32 patients with a PSA level ≥1.4 ng/ml, median 2.9 ng/ml (IQR 2.3–
4.2 ng/ml)
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Among all patients with metastatic PC, those with LN re-
lapse limited to the regional and/or retroperitoneal LNs may be
a distinct group with favourable outcomes if treated adequately.
Indeed, long-term complete biochemical remission has been
reported in patients who underwent PET/CT-guided surgical
resection of low-volume nodal metastases [28].Moreover, there
is a growing body of data indicating a beneficial impact of
surgical resection on survival in these patients [7]. In this study,
approximately four out of ten patients remained disease-free
during follow-up. This is in line with short-term outcomes
found in previous studies on SLND in patients with LN-only
recurrence based on choline PET or PSMA-11 PET [11, 28].
Nevertheless, long-term data on SLND based on PSMA-11
PET are still limited. Furthermore, a first randomized phase 3
prospective trial designed to determine whether PSMA-11
PET/CT molecular imaging can improve outcomes in patients
with early BCR following RP is currently recruiting, highlight-
ing the increasing role of PSMA-11 PET imaging in the tailor-
ing of salvage therapies for BCR after RP [29]. In addition,
accurate assessment of the presence of isolated LN relapse
and identifying the precise site of positive LN metastases is
important for site-directed surgery. Indeed, we have already
implemented a radioguided surgical approach to reduce poten-
tial risks, costs and morbidity of complete bilateral extended
SLND as done in our current study [30].
The main limitation of our study was the attribution of dis-
sected LNs to relative regions and subregions. This is known to
lead to systematic operator-dependent nomenclature errors that
would potentially have affected the results and limited their
reproducibility. The PPVin the subregion analysis ranging from
50% to 100% is likely to have resulted from attribution bias
from imaging versus surgery. Incomplete removal of involved
LNs during surgery also has to be taken into account, as the
PPV of PSMA-11 PET is known to be very high. Our study
population included a very selected group of patients with LN-
only recurrence. By excluding patients with bone or visceral
metastases, selection bias was, indeed, one of the limitations
of this study. About one-quarter of our cohort underwent
ADT prior to imaging, which might have affected the rate of
PSMA expression. However, in this relatively small study, sub-
group analysis did not show a difference in PSMA-11 PET
performance between patients with and without previous
ADT (data not shown). In addition, we also do not have data
about the extent or template of LN dissection at the time of RP.
However, we reported the number of LN harvested, which was
lower than the number found on SLND. Moreover, the number
of LN harvested is in agreement with the trend in contemporary
RP series in which the number of SLND procedures performed
and the number of LN harvested are generally decreasing. On
the other hand, this study included, to our knowledge, the larg-
est prospective consecutive cohort and evaluated the accuracy
of PSMA-11 PET/CT(MRI) in patients undergoing SLNDwith
bilateral extended templates. Besides, the regional and
subregional analyses in this study provide evidence of the ben-
efit of implementing site-directed surgery, as the NPVwas very
high. In this study, the number of LNs harvested during SLND
was relatively high, reflecting the completeness of template
dissection. Higher LN yield is known to be associated with a
higher likelihood of complications such as symptomatic
lymphocele. The rate of metastases in these LNs was in accor-
dance with previously reported rates for PSMA-11 PET [31].
Nevertheless, this rate was lower than that reported for PET
using choline derivatives (32%) [10].
Conclusion
In this prospective study, PSMA-11 PET/CT(MRI) had high
diagnostic accuracy in detecting and localizing LNmetastases
in men with BCR after RP. The high correlation between PET/
CT(MRI) and surgical findings provides evidence of the ben-
efit of site-directed therapeutic surgical intervention that
would avoid the possible morbidities of full bilateral extended
SLND in a subset of patients.
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